StockData
Cognition Therapeutics Inc logo

Cognition Therapeutics Inc (CGTX) company profile

CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.63−0.01 (-1.39%)

Close on Nov 17, 2026Market cap $59.90MP/E –Yield –

About Cognition Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Cognition is a clinical-stage biopharmaceutical company that discovers and develops small molecule drug candidates for age-related degenerative disorders of the central nervous system and retina. The company focuses on developing disease-modifying therapies designed to protect neuronal synapses from toxic protein oligomers. Its primary pipeline candidate is zervimesine, also identified as CT1812, an orally administered therapeutic being evaluated for Alzheimer’s disease and dementia with Lewy bodies. Its target recipients are patients experiencing cognitive decline, mild cognitive impairment, and associated neurodegenerative conditions.

In terms of clinical scale, more than 780 participants have received zervimesine across various clinical trials. The company conducts its ongoing Phase 2 START study across 45 clinical trial sites in collaboration with a specialized research consortium. Its regulatory engagements span agencies in the United States and Europe, including interactions with the United States Food and Drug Administration and guidance from the European Medicines Agency. The provided text does not state the location of the company's headquarters.

Summary of the business section of Cognition Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Cognition Therapeutics Inc
Founded
2007
Headquarters
Purchase, NY
Address
2500 Westchester Ave 10577
Phone
(412) 481-2210
Employees
14, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Philadelphia, PA

Stock & identifiers

Ticker
CGTX
Exchange
Nasdaq
IPO date
Oct 12, 2021
Shares outstanding
95M, Aug 4, 2026
Public float
$18.16M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1455365
CUSIP
19243B102
ISIN
US19243B1026
FIGI
BBG001J2P8S7
Share class FIGI
BBG001V0GFB9
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Lisa RicciardiCEO & President, Director1,754,702
John Brendan DoyleChief Financial Officer618,942
Anthony CaggianoChief Medical Officer874,906
Aaron G.L. FletcherDirector6,056,229
Bios Equity Partners, LPDirector–
Ellen B. RichstoneDirector83,500
Brett P. MoniaDirector73,500
BIOS Fund I, LPDirector5,505,905
Bios Equity Partners II, LPDirector6,014,500
BIOS Capital Management, LPDirector–
BIOS Fund II, LPDirector–
BIOS Fund I QP, LPDirector5,499,905
Jack A. KhattarDirector73,500
BIOS Advisors GP, LLCDirector6,048,500
BIOS Fund II QP, LPDirector–
Peggy WallaceDirector111,461
BIOS Memory SPV I, LPDirector6,081,229
BP Directors, LPDirector–
BIOS Equity Partners III, LPDirector–
BIOS Fund III, LPDirector6,048,500
BIOS Fund III QP, LPDirector5,499,905
BIOS Fund III NT, LPDirector5,483,841
BIOS Memory SPV II, LPDirector5,505,905
Leslie W. KreisDirector6,014,500
Cavu Advisors, LLCDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Lisa Ricciardi
President and Chief Executive Officer
$651.02K$396.46K$393.86K$18.30K$1.46M-4%
Anthony Caggiano, M.D., Ph.D.
Chief Medical Officer
$503.01K$185.26K$221.32K$18.30K$927.89K-19%
John Doyle
Chief Financial Officer
$460.58K$185.26K$202.65K$18.30K$866.79K+7%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 12, 2021
Offer price
$12.00
Securities offered
3,768,116
Gross proceeds
$45.22M
Exchange
Nasdaq
First trading day
Oct 11, 2021
First-day close
$12.30+2.5%
Lock-up ends (est.)
Apr 9, 2022

“The initial public offering price per share is $12.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 1, 2026, we had 14 employees, 14 of whom were full-time and 8 of whom were engaged in research and development activities.”

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 5, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 13, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 12, 2021IPOInitial public offering priced (424B4 prospectus)
Oct 6, 2021ListingRegistration of securities on an exchange (Form 8-A)
Dec 28, 2010Name changeName changed from COGNITION THERAPUTICS INC to Cognition Therapeutics Inc

See a number that looks wrong?